Latest Biotech News

Pfizer reinforced its obesity and diabetes case for berobenatide with new mid-stage results presented at ADA and reported by STAT+. In the VESPER-3 study, patients transitioned from weekly dosing...

The World Health Organization unveiled a six-month plan to stamp out the current Bundibugyo Ebola virus outbreak in Africa, including a major scale-up of point-of-care molecular diagnostics. WHO...

Roche said it will start a Phase 2 trial combining petrelintide and enicepatide this year, targeting obesity with an eye toward differentiating safety and efficacy across its amylin-based program....

Antibody–drug conjugates headlined first-in-human development at ASCO, according to BioCentury’s analysis of 137 FIH studies highlighted at the meeting. The review found that ADCs accounted for...

A Cell study led by Gabriel D. Victora at The Rockefeller University tracked thousands of B cells across more than 100 germinal centers in mice and found the process of affinity improvement is far...

Researchers in Cell Death Discovery reported that the transcription factor MSX1 plays a tumor-promoting role in cervical cancer. The study, published June 5, 2026, described new molecular...

A study in preclinical Alzheimer’s research reported that microglial CD31 hinders amyloid-beta clearance and worsens pathology in a 5×FAD mouse model. The work identified CD31 as a critical...

Fulcrum Therapeutics said it is laying off 85% of staff after discontinuing development of its lead sickle cell disease candidate, citing an FDA decision that left “no viable regulatory path.” The...

Medable launched an Agentic Accelerator Program to help life sciences companies deploy agentic AI across clinical development. The offering includes onboarding, integration support, governance,...

Eli Lilly reported additional safety and tolerability data for retatrutide, its next-generation obesity drug, in disclosures tied to the TRANSCEND-T2D-1 late-stage program. At the American...

Pfizer provided more details on berobenatide’s monthly dosing path for obesity, extending the dose schedule after weekly administration in its VESPER-3 mid-stage study. New data presented at the...

Roche said it will start a Phase 2 trial combining two obesity and metabolic candidates—petrelintide and enicepatide—during 2026. The company framed the approach as a way to test whether the...

Forbion appointed John McDonald as an operating partner focused on business development and M&A, bringing experience across biopharma and earlier corporate strategy roles. The hire follows...

The House Appropriations Committee directed the FDA to speed up IND sign-off timelines, arguing the agency should reform how it processes new clinical trial authorizations to keep pace with global...

Bio-Techne and Refeyn launched an integrated characterization workflow for bispecific antibodies and biosimilars, combining charge/variant separation with single-molecule aggregation and size...

Fulcrum Therapeutics said it is axing most roles and discontinuing development of its sickle cell disease candidate following FDA concerns about the benefit-risk profile. The company reported that...

WHO unveiled a six-month Bundibugyo Ebola outbreak plan centered on scaling point-of-care molecular diagnostics alongside reference laboratory capacity. The initiative, supported by Africa CDC,...

UK Biobank said it will seek to recall downloads after a health data breach in which researchers’ data were advertised for sale, including on a Chinese e-commerce platform. The group said it will...

Contraline secured $92.5 million to advance two male contraceptive candidates, including a once-daily topical gel and an implantable option. The funding is intended to move both programs forward...

Eli Lilly shared additional safety and tolerability data for retatrutide at the American Diabetes Association meeting, extending the profile of its next-generation obesity program. In participants...